US Angel Investors in Israeli Startups: The Tax Reality

An American investor writes a USD 150,000 check into a promising Tel Aviv startup and hears, from the founders and from a few enthusiastic blog posts, that Israel offers a generous tax break for angels. It is true that such a law exists. What no one tells the investor is that the break is a credit against Israeli tax, and this particular investor, a resident of Boston with no Israeli income, has no Israeli tax for it to reduce. The headline benefit, in their hands, is worth close to nothing. Meanwhile a set of US rules they have not thought about, with names like PFIC and Subpart F, quietly begins to shape what the investment will actually return.

This is the gap this guide is written to close. Israel genuinely rewards investment in its high-tech sector, and there are real tax advantages for a US investor here. They are just not always the ones the marketing points to. Getting the benefit means understanding which Israeli provision helps a non-resident, which one does not, and how the US side treats a foreign startup investment regardless of what Israel does.

For the founder's side of these questions, our guide comparing a US LLC and an Israeli company for non-resident founders covers the structuring choices that determine much of this.

The Angels Law: Real, but Not Always for You

Israel's current angel incentive is the Law for the Encouragement of Knowledge-Intensive Industry, passed as a temporary order in 2023. It revived, in a new form, an earlier "Angels Law" that had lapsed at the end of 2019. It offers an individual investor in a qualifying Israeli research-and-development company a credit against Israeli tax, calculated as the amount invested multiplied by the investor's applicable Israeli capital gains rate, on investments up to ILS 4 million (roughly USD 1.1 million). To keep the benefit the investor must hold the shares for at least three years.

Read the mechanism closely and the limitation becomes obvious. It is a credit against Israeli tax. A US resident who invests as a foreign individual, with no salary, rent, or business income sourced to Israel, has no Israeli tax bill for that credit to erase. The benefit does not convert into cash, and it does not carry over to your US return. It sits unused.

Who does it help? An investor with Israeli tax exposure, for example someone who also earns Israeli-source income, or who expects a taxable Israeli gain elsewhere that the credit could shelter. For most purely US-based angels, the Angels Law is a reason to feel good about the ecosystem rather than a line item on their own return.

In Practice: Under the Law for the Encouragement of Knowledge-Intensive Industry (Temporary Order) 2023, an individual investing in a qualifying R&D company receives a credit against Israeli tax equal to the investment multiplied by the capital gains rate, capped at an ILS 4 million investment, with a three-year holding requirement. The benefit is claimed through the Israel Tax Authority and the window runs to 31 December 2026. The company must itself qualify, meaning, among other tests, that its annual technological revenue does not exceed ILS 4.5 million and its average research spending is at least 7% of income, so the startup's own numbers decide whether the benefit is even available.

The Provision That Actually Helps a US Angel

Here is the Israeli tax break that matters for most Americans, and it is not the Angels Law. Section 97 of the Income Tax Ordinance exempts a non-resident from Israeli capital gains tax on the sale of securities in an Israeli company. If you buy shares in a Tel Aviv startup as a US resident and sell them years later at a profit, Israel generally does not tax that gain at all, provided the company is not essentially a holder of Israeli real estate and the usual conditions are met.

This is a meaningful advantage. An Israeli resident selling the same shares would face capital gains tax of 25%, or more where they are a substantial shareholder. As a non-resident, you can be exempt from that layer entirely. The exemption is what makes Israeli startup equity attractive to a foreign investor from a purely Israeli-tax standpoint, far more than any credit.

The exemption is not self-executing, though, and that trips people up. When you sell, the buyer or the company's transfer agent may be required to withhold Israeli tax unless you produce proof of your exemption. That proof is a withholding certificate from the assessing officer.

In Practice: Section 97(b3) of the Income Tax Ordinance exempts a non-resident's capital gain on the securities of an Israeli company, against a rate that would otherwise reach 25% or more. To stop the buyer withholding at closing, your representative applies to the Israel Tax Authority for a withholding exemption certificate (אישור פטור מניכוי מס במקור), which for a clean non-resident case is generally issued within a few weeks. Sell without it and you can watch 25% of your proceeds withheld and then spend months reclaiming a tax you never actually owed. Our guide to the capital gains exemption for foreign investors in Israeli shares covers the conditions in depth.

The US Side Is Where Most of the Money Is Decided

Whatever Israel does or does not tax, you remain a US person taxed on worldwide income, and the US treatment of a foreign startup investment is often the larger factor in your net return. Three rules deserve your attention before you sign.

PFIC. A passive foreign investment company is a foreign corporation that is heavy on passive income or passive assets. A pre-revenue startup sitting on a pile of raised cash can, awkwardly, meet the passive-asset test even though its purpose is anything but passive. If your Israeli company is a PFIC, US tax rules can turn your eventual gain into ordinary income with an interest charge, unless you make a timely election such as a qualified electing fund election, which requires cooperation and annual information from the company.

QSBS. The qualified small business stock exclusion under Section 1202 can exempt a large slice of gain from US tax, but only for stock of a US domestic C corporation. An Israeli company does not qualify. This single fact drives many "flip" transactions, where an Israeli startup reorganizes under a Delaware parent so that US investors can preserve QSBS eligibility.

CFC and Subpart F. If US shareholders together own more than half the company and you hold at least 10%, the company can be a controlled foreign corporation, pulling you into Subpart F and GILTI inclusions and Form 5471 filing, meaning you can owe US tax on the company's earnings before you have received a cent.

None of this is a reason to avoid Israeli startups. It is a reason to know the structure before you invest, because the difference between buying into an Israeli company directly and buying into a Delaware parent that owns the Israeli company can be worth more than any incentive on either side.

The Treaty in the Background

The United States and Israel have a double-tax treaty, and it does useful work at the edges. It reduces Israeli withholding on dividends a US investor receives from an Israeli company, and it gives you a framework for claiming a US foreign tax credit for Israeli tax you do pay, so the same income is not fully taxed twice. For an early-stage angel the treaty rarely drives the decision, since startups seldom pay dividends, but it becomes relevant if the company matures into a payer or if any Israeli tax is withheld that you need to credit at home. Our overview of Israel's R&D grants and tax benefits sits alongside the treaty as part of the wider incentive picture.

What Often Goes Wrong

Common Mistake: A US angel invests directly into the Israeli company to chase the Angels Law credit, then discovers at exit that the credit was useless to them for lack of Israeli tax, that the shares never qualified for the Section 1202 QSBS exclusion because the issuer was foreign, and that the company was a PFIC for the years they held it. The result is a gain taxed at ordinary US rates with an interest charge, instead of a gain that a Delaware flip could have made eligible for the QSBS exclusion. On a USD 500,000 gain, the difference between QSBS-exempt and PFIC-ordinary treatment can exceed USD 150,000 in US tax, all decided by a structuring choice made at the start.

The second recurring error is procedural rather than structural: selling the Israeli shares without first securing the non-resident withholding exemption certificate, and losing the use of 25% of the proceeds for the months it takes to reclaim them.

Practical Checklist

• Confirm whether the incentive being pitched to you is an Israeli tax credit you can actually use, or one that assumes an Israeli tax bill you do not have.
• Ask whether you will hold shares in the Israeli company directly or in a US parent, and understand the QSBS and PFIC consequences of each.
• Establish, before investing, whether the company will provide the annual information a US investor needs for a PFIC election.
• Plan the non-resident capital gains exemption early, and build the withholding-certificate step into any future sale.
• Check whether your stake, combined with other US holders, could make the company a controlled foreign corporation for you.
• Price the annual US compliance cost, Forms 8621 or 5471, into your view of the deal.
• Get Israeli and US tax advice that talk to each other, because the structure has to work on both sides at once.

Speak With an Israeli Attorney

Investing in an Israeli startup as a US angel is less about capturing a headline incentive than about structuring the holding so the Israeli exemption and the US rules both work in your favor. An Israeli attorney, working with your US adviser, can confirm whether a benefit is usable in your hands, secure the non-resident exemption when you exit, and flag the structuring choices that decide your after-tax return.

Contact us for a confidential initial consultation.